Assessing liver function

Current Opinion in Critical Care

Volumn 13, Issue 2, 2007, Pages 207-214

  Sakka, Samir G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Critical care medicine; Liver function; Monitoring

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMINO ACID; AMINOPHENAZONE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BROMSULFOPHTHALEIN; CAFFEINE; GALACTOSE; GAMMA GLUTAMYLTRANSFERASE; GLYCINE DERIVATIVE; HYPERTENSIVE FACTOR; ILOPROST; INDOCYANINE GREEN; LIDOCAINE; MONOETHYLGLYCINXYLIDIDE; PROSTACYCLIN; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; CHOLESTASIS; CRITICALLY ILL PATIENT; DRUG METABOLISM; ENZYME ASSAY; HALF LIFE TIME; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER TRANSPLANTATION; PATIENT MONITORING; PLASMA CLEARANCE; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AMINOPYRINE; CAFFEINE; CRITICAL CARE; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; SULFOBROMOPHTHALEIN;

EID: 33847293718     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328012b268     Document Type: Review

References (71)

1. Paxian M, Bauer I, Rensing H, et al. Recovery of hepatocellular ATP and pericentral apoptosis after hemorrhage and resuscitation. FASEB J 2003; 17:993-1002.
2. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci 1988; 33:1601-1614.
3. Kaplan MM. Alkaline phosphatase. Gastroenterology 1972; 62:452-468.
4. Abraham SC, Furth EE. Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 1995; 59:740-746.
5. Arrigoni A, Gindro T, Aimo G, et al. Monoethylglycinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994; 20:383-387.
6. Kimura S, Yoshioka T, Shibuya M, et al. Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001; 29:1159-1163.
7. Nonami T, Nakao A, Kurokawa T, et al. Blood loss and ICG clearance as best prognostic markers of posthepatectomy liver failure. Hepatogastroenterology 1999; 46:1669-1672.
8. Eguchi H, Umeshita K, Sakon M, et al. Presence of active hepatitis associated with liver cirrhosis is a risk factor for mortality caused by posthepatectomy liver failure. Dig Dis Sci 2000; 45:1383-1388.
9. 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004; 24:117-123.
10. (ICG) value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation. Liver Transpl 2006; 12:605-613. This study emphasized the usefulness of ICG-PDR in the field of liver transplantation.
11. Oellerich M, Burdelski M, Lautz HU, et al. Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation 1991; 51:801-806.
12. Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant Proc 2006; 38:801-802.
13. Sakka SG, Koeck H, Meier-Hellmann A. Measurement of indocyanine green plasma disappearance rate by two different dosages. Intensive Care Med 2004; 30:506-509.
14. Sakka SG, Reinhart K, Meier-Hellmann A. Comparison of invasive and noninvasive measurements of indocyanine green plasma disappearance rate in critically ill patients with mechanical ventilation and stable hemodynamics. Intensive Care Med 2000; 26:1553-1556.
15. Godje O, Peyerl M, Seebauer T, et al. Reproducibility of double indicator dilution measurements of intrathoracic blood volume compartments, extravascular lung water, and liver function. Chest 1998; 113:1070-1077.
16. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122:1715-1720.
17. Pollack DS, Sufian S, Matsumoto T. Indocyanine green clearance in critically ill patients. Surg Gynecol Obstet 1979; 149:852-854.
18. Kholoussy AM, Pollack D, Matsumoto T. Prognostic significance of indocyanine green clearance in critically ill surgical patients. Crit Care Med 1984; 12:115-116.
19. Sakka SG, Meier-Hellmann A. Indocyanine green for the assessment of liver function in critically ill patients. In: Vincent JL, editor. Yearbook of Intensive Care and Emergency Medicine. Berlin, Heidelberg, New York: Springer-Verlag; 2001. pp. 611-618.
20. Kortgen A, Lindemann W, Bauer M. Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock. Dtsch Med Wochenschr 2004; 129:2590-2593.
21. Poeze M, Solberg BC, Greve JW, Ramsay G. Monitoring global volume-related hemodynamic or regional variables after initial resuscitation: What is a better predictor of outcome in critically ill septic patients? Crit Care Med 2005; 33:2494-2500.
22. Hashimoto M, Watanabe G. Hepatic parenchymal cell volume and the indocyanine green tolerance test. J Surg Res 2000; 92:222-227.
23. Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 2000; 191:381-388.
24. Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997; 84:1255-1259.
25. Ishikawa M, Yogita S, Miyake H, et al. Clarification of risk factors for hepatectomy in patients with hepatocellular carcinoma. Hepatogastroenterology 2002; 49:1625-1631.
26. Hemming AW, Scudamore CH, Shackleton CR, et al. Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg 1992; 163:515-518.
27. Ohwada S, Kawate S, Hamada K, et al. Perioperative real-time monitoring of indocyanine green clearance by pulse spectrophotometry predicts remnant liver functional reserve in resection of hepatocellular carcinoma. Br J Surg 2006; 93:339-346. This paper deals with the use of ICG-PDR for assessment of functional liver reserve in the field of liver resection.
28. Wesslau C, Krüger R, May G. Clinical investigations using indocyanine green clearance for evaluation of liver function in organ donors. Transplantology 1994; 5:7-9.
29. Jalan R, Plevris JN, Jalan AR, et al. A pilot study of indocyanine green clearance as an early predictor of graft function. Transplantation 1994; 58:196-200.
30. Krenn CG, Schäfer B, Berlakovich GA, et al. Detection of graft nonfunction after liver transplantation by assessment of indocyanine green kinetics. Anesth Analg 1998; 87:34-36.
31. Von Spiegel T, Scholz M, Wietasch G, et al. Perioperative monitoring of indocyanine green clearance and plasma disappearance rate in patients undergoing liver transplantation. Anaesthesist 2002; 51:359-366.
32. Sakka SG. Indocyanine green plasma disappearance rate during relief of increased abdominal pressure. Intensive Care Medicine 2006; Oct 20 [Epub ahead of print].
33. Inderbitzin D, Muggli B, Ringger A, et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J Gastrointest Surg 2005; 9:1155-1161.
34. Tsukada K, Sakaguchi T, Aono T, et al. Indocyanine green disappearance enhanced by prostaglandin E1 in patients with hepatic resection. J Surg Res 1996; 66:64-68.
35. Orii R, Sugawara Y, Hayashida M, Yamada Y, et al. Effects of amrinone on ischaemia-reperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin E1. Br J Anaesth 2000; 85:389-395.
36. Devlin J, Ellis AE, McPeake J, et al. N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Crit Care Med 1997; 25:236-242.
37. Joly LM, Monchi M, Cariou A, et al. Effects of dobutamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock. Am J Respir Crit Care Med 1999; 160:1983-1986.
38. Lehmann C, Taymoorian K, Wauer H, et al. Effects of the stable prostacyclin analogue iloprost on the plasma disappearance rate of indocyanine green in human septic shock. Intensive Care Med 2000; 26:1557-1560.
39. Michelet P, Roch A, Gainnier M, et al. Influence of support on intra-abdominal pressure, hepatic kinetics of indocyanine green and extravascular lung water during prone positioning in patients with ARDS: a randomized crossover study. Crit Care 2005; 9:R251-R257.
40. Stehr A, Ploner F, Traeger K, et al. Plasma disappearance of indocyanine green: a marker for excretory liver function? Intensive Care Med 2005; 31:1719-1722. This animal experimental study questioned the meaning of ICG-PDR as a marker of liver cell function and suggests that hepatic blood flow more than cellular function may be assessed by this parameter.
41. Sakka SG, van Hout N. Relation between indocyanine green (ICG) plasma disappearance rate and ICG blood clearance in critically ill patients. Intensive Care Med 2006; 32:766-769. This paper shows that ICG-PDR is correlated well with ICG blood clearance.
42. Fazakas J, Mandli T, Ther G, et al. Evaluation of liver function for hepatic resection. Transplant Proc 2006; 38:798-800.
43. Jodynis-Liebert J, Flieger J, Matuszewska A, Juszczyk J. Serum metabolite/caffeine ratios as a test for liver function. J Clin Pharmacol 2004; 44:338-347.
44. Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4:38-46.
45. Chopra S, Griffin PH. Laboratory tests and diagnostic procedures in evaluation of liver disease. Am J Med 1985; 79:221-230.
46. Babb RR, McPherson JR. The sulfobromophthalein sodium test: a review. Manit Med Rev 1966; 46:124-126.
47. Yamanaka N, Shimizu S, Chijiiwa K, et al. Hepatectomy and marked retention of indocyanine green and bromosulfophtalein. Hepatogastroenterology 2001; 48:1450-1452.
48. Conti F, Dousset B, Cherruau B, et al. Use of lidocaine metabolism to test liver function during the long-term follow-up of liver transplant recipients. Clin Transplant 2004; 18:235-241.
49. Clowes GH Jr, McDermott WV, Williams LF, et al. Amino acid clearance and prognosis in surgical patients with cirrhosis. Surgery 1984; 96:675-685.
50. Bianchi G, Marchesini G, Vilstrup H, et al. Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: a simplified method. Hepatology 1991; 13:460-466.
51. Christensen E, Bremmelgaard A, Bahnsen M, et al. Prediction of fatality in fulminant hepatic failure. Scand J Gastroenterol 1984; 19:90-96.
52. Jochum C, Beste M, Penndorf V, et al. Quantitative liver function tests in donors and recipients of living donor liver transplantation. Liver Transpl 2006; 12:544-549.
53. Addario L, Scaglione G, Tritto G, et al. Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 2006; 18:713-720. This recent study suggested that neither single nor repeated determinations of GEC and MEGX are superior to Child classification or MELD score in predicting prognosis of patients with viral cirrhosis.
54. Oellerich M, Armstrong VW. The MEGX test: a tool for the real-time assessment of hepatic function. Ther Drug Monit 2001; 23:81-92.
55. Swart EL, van der Hoven B, Groeneveld AB, et al. Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol 2002; 53:133-139.
56. Lee WC, Chen MF. Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg 2005; 12:23-26.
57. Oellerich M, Burdelski M, Lautz HU, et al. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14:1029-1034.
58. Schroter J, Wandel C, Bohrer H, et al. Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia 1995; 50:850-854.
59. Maynard ND, Bihari DJ, Dalton RN, et al. Liver function and splanchnic ischemia in critically ill patients. Chest 1997; 111:180-187.
60. Rank N, Michel C, Haertel C, et al. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med 2000; 28:3799-3807.
61. Ercolani G, Grazi GL, Calliva R, et al. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. Surgery 2000; 127:464-471.
62. Oellerich M, Schutz E, Polzien F, et al. Influence of gender on the mono-ethylglycinexylidide test in normal subjects and liver donors. Ther Drug Monit 1994; 16:225-231.
63. Wang JS, Backman JT, Wen X, et al. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 1999; 85:201-205.
64. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. Pharmacol Exp Ther 1995; 274:673-677.
65. Orlando R, Padrini R, Perazzi M, et al. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 2006; 79:489-499.
66. Ascione R, Talpahewa S, Rajakaruna C, et al. Splanchnic organ injury during coronary surgery with or without cardiopulmonary bypass: a randomized, controlled trial. Ann Thorac Surg 2006; 81:97-103. These authors studied the changes in liver function during off-pump and on-pump cardiac surgery.
67. Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med 1975; 83:632-638.
68. Baker AL, Krager PS, Kotake AN, Schoeller DA. The aminopyrine breath test does not correlate with histologic disease severity in patients with cholestasis. Hepatology 1987; 7:464-467.
69. Merkel C, Bolognesi M, Bellon S, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33:836-842.
70. Takeda M, Furuse A, Kawauchi M, et al. Estimation of functional liver reserve in patients before cardiac surgery using antipyrine plasma clearance test. J Cardiovasc Surg (Torino) 1999; 40:817-823.
71. Fan ST, Wang QS, Lo CM, et al. Evaluation of indocyanine green retention and aminopyrine breath tests in patients with malignant biliary obstruction. Aust N Z J Surg 1994; 64:759-762.